IP Group plc

🔬Iksuda Therapeutics shares encouraging early data on new cancer treatment IKS014   Portfolio company Iksuda Therapeutics has shared promising early results from its Phase 1 trial of IKS014, a new treatment for advanced cancers that express the HER2 protein.   The drug is designed to deliver cancer-killing agents directly to tumour cells and is being tested in patients with a range of HER2+ cancers.   Dr. David Simpson, Chief Executive Officer, Iksuda Therapeutics, said: “We are hugely encouraged by these data, which illustrates the potential of IKS014 to improve outcomes and address the clinical unmet need across various HER-2 positive cancers, including treatment of those patients which are refractory to prior therapy options.” 🔗Link to full press release in comments

Another exciting announcement from the Iksuda team! 👇 Iksuda presents encouraging IKS014 Phase 1 data at ESMO Read all about it here https://lnkd.in/gfzQ3JSM #ESMO2025

📢 Our October newsletter is now live — here’s some of what’s happened recently: 🔬 Potential future royalty income from Metsera/Pfizer* obesity drug candidates 🏆 IP Group plc maintains position as the UK’s lead investor in spinouts, with Parkwalk Advisors, our EIS fund management business, continuing to set the pace 📰 Monolith to be Acquired by CoreWeave 🔗 Link to full newsletter in comments 📩Sign up to receive our newsletter: https://bit.ly/444qDHW *Pfizer, Inc. and Metsera announced they had reached a definitive agreement for Pfizer to acquire Metsera and its next-generation obesity portfolio.

🧪Artios shares promising early results for new cancer treatment   Portfolio company Artios Pharma has announced encouraging early results from its Phase 1/2a study of ART6043.   ART6043 targets Polθ, a key DNA repair enzyme that is overexpressed in many cancers but present at low levels or absent in most healthy tissues.   Many cancers rely on this protein to survive, especially when other treatments stop working. By blocking Polθ, ART6043 aims to enhance anti-tumor activity   Ian Smith, Chief Medical Officer of Artios said: “The emerging clinical data validate our approach to inhibit Polθ to selectively cripple tumor cells and exploit a cancer’s dependency on DNA repair. The initial data and efficacy signals in the relevant genetic background are encouraging, and we look forward to advancing ART6043’s clinical development to realize its potential to increase the effectiveness of PARP inhibition, where resistance to standard of care has become increasingly prevalent.” 🔗Link to full press release in comments

A proud moment for Genomics, and our team who have developed this transformational tool for drug target discovery.

📢Genomics is delighted to announce the official launch of Mystra: the world’s first and original AI-enabled human genetics platform, now available to transform drug target discovery and clinical development. Over the last 10 years, we have ingested, harmonised, and quality-controlled what is now the world’s largest and most diverse human genotype-phenotype database. Mystra offers biopharma partners proven analytical power to turn months of R&D into minutes, dramatically increasing the availability of quality genetic insights and, therefore, the probability of honing in on successful drug candidates. 📰Read the full press release here: https://lnkd.in/eA92HD4K #Genomics #Mystra #DrugDiscovery #Innovation #LifeSciences #PrecisionMedicine #News #CompanyNews #IndustryNews #ASHG25

🧬Congratulations to portfolio company Mission Therapeutics, which has raised $13.3 million to progress first-in-class Parkinson’s disease candidate MTX325 through clinical trials. We’re proud to have supported this round and to continue backing Mission’s ground-breaking work. 👇 Link to full release in comments

🚨News Alert🚨   Mission Therapeutics announces $13.3 million raise from current investors to fully execute its Phase Ib proof-of-mechanism study of MTX325 in patients with #ParkinsonsDisease (PD). #MTX325 is a first-in-class and potentially disease-modifying treatment for PD, which works by enhancing mitophagy to protect dopamine-producing neurons.   The raise follows the successful completion of Phase Ia studies in healthy volunteers which showed MTX325 to be safe and tolerable, and included PET scans which confirmed MTX325 penetrates functional brain tissue.   This raise further demonstrates the continued support of our syndicate of world-leading investors in our mission to advancing MTX325 through the clinic.   Read the full press release here: https://bit.ly/46RzKk9   #Parkinsons #DUBinhibitors #neurodegenerativediseases

🗓️ In just one week, on Thursday 23rd October, our CFOO David Baynes will be presenting at the Proactive One2One Investor Forum, where he'll be discussing progress at IP Group. 🔗 Sign up to attend in person: https://bit.ly/3IRpHSQ